Home

David Hollander

CIK 1793796 · CMO & Global Therapeutics Lead · last filed 2026-06-12

David Hollander is a CMO & Global Therapeutics Lead who has filed 13 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for KPRX, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$16.3K, making them a net seller over the disclosed history.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

13

Lifetime Open-Market Net

-$16.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KPRX Director — $2.57 — $0 6 2026-06-12
Revance Therapeutics, Inc. (RVNC) Delisted CMO & Global Therapeutics Lead 0 $3.65 $0 -$16.3K 2 2025-02-06
AERIE PHARMACEUTICALS INC (AERI) Delisted Chief R&D Officer 30,749 $15.25 $468.9K $0 5 2022-02-08

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-12 KPRX Grant (A) — $0 EDGAR
2025-04-02 KPRX Grant (A) — $0 EDGAR
2025-02-06 Revance Therapeutics, Inc. (RVNC) Delisted Mixed −104,945 -$35.5K EDGAR
2024-11-19 Revance Therapeutics, Inc. (RVNC) Delisted Sell (S) −3,908 -$16.3K EDGAR
2024-07-03 KPRX Grant (A) — $0 EDGAR
2023-10-03 KPRX Grant (A) — $0 EDGAR
2023-03-07 KPRX Grant (A) — $0 EDGAR
2022-02-08 AERIE PHARMACEUTICALS INC (AERI) Delisted Tax (F) −927 -$6.5K EDGAR
2022-02-03 KPRX Grant (A) — $0 EDGAR
2021-11-15 AERIE PHARMACEUTICALS INC (AERI) Delisted Tax (F) −2,162 -$26.1K EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.